Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207803 | 0.87 | NPC1 (0.68) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL3782118 | 0.87 | NPC1 (0.68) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL3787582 | 0.85 | NPC1 (0.61) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL30207785 | 0.83 | PLAU (0.57) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL30522295 | 0.82 | NPC1 (0.69) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL2233522 | 0.82 | NPC1 (0.69) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL16193532 | 0.82 | NPC1 (0.69) | NPC1RAB9ACASP3MGLLPOLB | |
| Formic Acid SCHEMBL27606526 | 0.82 | NPC1 (0.61) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL3781708 | 0.81 | NPC1 (0.64) | NPC1RAB9ACASP3MGLLPOLB | |
| SCHEMBL17420472 | 0.81 | NPC1 (0.68) | NPC1RAB9ACASP3MGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | NPC1 724/4885RAB9A 1357/4885CASP3 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.